Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -183.90% is 202% below its 5-year average of -60.95%, near the high end of its 5-year range (-2086.88%–0.00%).
4.43% below its 12-month average of -176.09%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -310.77%.
NET PROFIT MARGIN
-183.90%
NET PROFIT MARGIN AVG TTM
-176.09%
NET PROFIT MARGIN AVG 3Y
-150.93%
NET PROFIT MARGIN AVG 5Y
-60.95%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-4.43%
CURRENT VS 3Y AVG
-21.85%
CURRENT VS 5Y AVG
-201.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 565 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Invivyd, Inc.
Market Cap
$249.41M
Net Profit Margin
-183.90%
TTM Avg
-176.09%
3Y Avg
-150.93%
5Y Avg
-60.95%
Market Cap
$244.74M
Net Profit Margin
-2543.74%
TTM Avg
-5120.97%
3Y Avg
-6084.02%
5Y Avg
-4060.63%
Market Cap
$243.81M
Net Profit Margin
N/A
TTM Avg
-26.91%
3Y Avg
-35.21%
5Y Avg
-46.29%
Market Cap
$243.66M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$255.98M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2265.94%
5Y Avg
-2185.44%
Market Cap
$241.56M
Net Profit Margin
-155582.08%
TTM Avg
-91683.52%
3Y Avg
-62749.43%
5Y Avg
-41832.95%
Market Cap
$240.76M
Net Profit Margin
-4.52%
TTM Avg
-4.68%
3Y Avg
-9.38%
5Y Avg
-10.81%
Market Cap
$236.31M
Net Profit Margin
-26.97%
TTM Avg
-50.02%
3Y Avg
-94.39%
5Y Avg
-87.59%
Market Cap
$239.06M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Invivyd, Inc. (IVVD) | $249.41M | -183.90% | -176.09% | -150.93% | -60.95% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $244.74M | -2543.74% | -5120.97% | -6084.02% | -4060.63% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | N/A | -26.91% | -35.21% | -46.29% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.66M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $255.98M | 0.00% | 0.00% | -2265.94% | -2185.44% |
| InflaRx N.V. (IFRX)vs › | $241.56M | -155582.08% | -91683.52% | -62749.43% | -41832.95% |
| High Tide Inc. (HITI)vs › | $240.76M | -4.52% | -4.68% | -9.38% | -10.81% |
| Biodesix, Inc. (BDSX)vs › | $236.31M | -26.97% | -50.02% | -94.39% | -87.59% |
| Galectin Therapeutics Inc. (GALT)vs › | $239.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| AC Immune S.A. (ACIU)vs › | $260.03M | -249.94% | -1079.05% | -1080.63% | -787.30% |
Operating Margin
-104.0%
Net Profit Margin
-183.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -310.77% |
| 2026-03-31 | -301.22% |
| 2025-12-31 | -64.33% |
| 2025-09-30 | -79.75% |
| 2025-06-30 | -124.38% |
| 2025-03-31 | -144.10% |
| 2024-12-31 | -133.45% |
| 2024-09-30 | -653.11% |
| 2024-06-30 | -2086.88% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
